Pharmaceutical Ethics

Jim Cramer is no fan of Mylan NV (NASDAQ: MYL) and how it handled the EpiPen controversy. Cramer ranted on Thursday's "Squawk Box" that EpiPen has to be a "much bigger source" of Mylan's profit than the company is letting on and he would like to see the company's...